Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.» Read More
Roche is buying biotech company InterMune for $74 per share, reports CNBC's Meg Tirrell.
Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.
Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.
Asian equities traded mixed on Monday as a cautious sentiment set in after fresh conflict in Ukraine at the weekend.
Chugai shares rose 21 percent following a media report that Roche Holding AG is in talks to buy the almost 40 percent stake in the Japanese firm.
Milind Sabnis, Associate Director for Healthcare Practice at Frost & Sullivan, discusses news that Roche is looking to acquire Japanese drug giant Chugai Pharmaceutical for about $10 billion.
U.S. stocks ended the week mixed after news of fresh conflict between Russia and Ukraine.
Take a look at some of Friday's midday movers:
Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
European shares closed higher on Thursday, after a business activity index showed the euro zone rebounded in July.
Roche confirmed its full-year outlook, but posted profit that missed expectations following an impairment charge at its diagnostics business.
Severin Schwan, CEO of Roche, says the company would consider a large acquisition if the "price is right" despite concerns over high valuations.
Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.
Some of Monday's midday movers:
Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.
Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.
U.S. stocks closed mixed on Wednesday as the Dow and S&P 500 pushed into uncharted territory ahead of a government jobs report.
As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.
CNBC's Meg Tirrell and Daniel O'Day, Roche Holdings COO, discuss the latest developments in immunotherapy and treating bladder cancer.